Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label continuation study of methylthioninium chloride in Alzheimer's disease
2007-002470-59Phase 2Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of methylene blue in Alzheimer's disease (AD) (2 arms), sponsored by TauRx Therapeutics Ltd. Primary endpoints: Change in cognitive function from baseline measured by ADAS-cog and Long-term safety and tolerability. Started Jun 2007; status: completed.
02
Drugs
methylene blue
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-002470-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002470-59.